Journal Scans
Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer
Pertuzumab Added to Trastuzumab/Docetaxel Benefits Metastatic Breast Cancer
J Baselga, J Cortes, S-B Kim, S Swain, et al
Yes
20111107
2011 Dec 7
N Engl J Med
Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer
N Engl J Med. 2011 Dec 7;[Epub Ahead of Print], J Baselga, J Cortes, S-B Kim, S Swain, et al
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Breast cancers that express or amplify genes of human epidermal growth factor receptor 2 (HER2) typically are more aggressive and are associated with a poor prognosis. Trastuzumab, which is an anti-HER2 humanized monoclonal antibody, improves survival compared with chemotherapy alone in patients with HER2+ metastatic breast cancer. Pertuzumab is another humanized monoclonal antibody that binds to a different epitope of the HER2 extracellular domain. Since trastuzumab and pertuzumab bind to different...
